Neisserial Surface Protein A Vaccine Antigens With Decreased Binding To Human Complement Factor H

Tech ID: 34514 / UC Case 2022-028-0

VALUE PROPOSITION

There is currently a lack of licensed vaccine for protection against gonorrhea and other gonococcal diseases and a limited protection afforded by meningococcal group B vaccines, especially in infants. There are ~ 100 M cases of gonorrhea each year globally, making it the second most common bacterial sexually transmitted infection worldwide.

TECHNOLOGY DESCRIPTION

UCSF investigators have developed mutant versions of several bacterial antigens and have shown that that these increased vaccine immunogenicity and protection compared to their native counterparts in relevant animal models.

CONTACT

Jessica Chan

jessica.chan2@ucsf.edu

tel: .



OTHER INFORMATION

KEYWORDS

factor H binding protein, meningococcal serogroup B vaccine, Immune selection, Neisseria meningitidis, bacterial antigens, vaccine immunogenicity

CATEGORIZED AS

- **Biotechnology**
  - Health
- **Medical**
  - Disease: Infectious Diseases
  - Therapeutics
  - Vaccines

RELATED CASES

2022-028-0

ADDRESS

UCSF

Innovation Ventures

600 16th St, Genentech Hall, S-272,

San Francisco,CA 94158

CONTACT

Tel:

innovation@ucsf.edu

https://innovation.ucsf.edu

Fax:

CONNECT

Follow Connect

© 2026, The Regents of the University of California

Terms of use Privacy Notice